Tagged with Article

Switzerland Bairbre Hickie, General Manager at Takeda, discusses the company’s strategic priorities in Switzerland, focusing on its commitment to bringing innovative treatments to patients and its role in advancing the life sciences ecosystem. In this interview, Hickie explores Takeda’s approach to partnerships, its focus on rare diseases and oncology, and how…

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…

Italy Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of liquidity in the market, including amongst the family businesses … and there are now a lot of companies looking for…

Pharma France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a tradition of openness and understanding of dermatology. [France is] a unique environment for the growth of dermo-cosmetic brands. French dermatologists have a…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in order to succeed. From 2014 to 2015, the total Mexican pharmaceutical market displayed a strong 5.3 percent growth to reach…

Pharma Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of innovation. Switzerland is frequently considered one of the most entrepreneurial and competitive countries in the world. As Thomas Cunei, secretary general of Interpharma, the association that represents 92…

Pharma After a number of years of difficulty post-2008 and the euro-debt crisis, Ireland’s pharma manufacturing industry and economy in general is now firmly on the up. The local Irish pharma market is still under some pressure following years of austerity which saw the average price of a reimbursable medicine cut…

Pharma Since gaining independence in 1965, Singapore has invested heavily in moving beyond being a mere supplier of low cost labor like many of its Asian neighbors and pivoting into a more knowledge-based and innovation-intensive economy. Chemicals, engineering, and electronics have always served as key manufacturing segments, but only starting from…

Pharma Digitalization, a hot topic throughout the healthcare and life sciences industry, is having a major effect in Italy through more personalized home care for patients, allowing the government to cut costs, and enabling greater public access to innovative medical technologies. Telemedicine, a key differentiator in tender processes, is not yet used…

Hungary Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in a market where the reimbursement scheme is highly restrictive, OTC has often been seen as a consistent and reliable area…

Hungary Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception.  Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which is below the average of 9.3 percent across OECD countries. Moreover, only 63 percent was funded through public sources. Furthermore, fresh data…